AI-powered digital pathology model validated to predict prostate cancer outcomes after surgery. Outperforms standard clinical tools and offers a scalable, low-cost alternative to genomic testing.
PSMA PET and theranostics are transforming prostate cancer staging and treatment. Review current imaging tracers, Lu-177 therapy, and future alpha-emitter strategies.
Micro-ultrasound matches MRI for prostate cancer detection in whole-mount analysis, confirming biopsy-based results from the OPTIMUM trial—while MRI remains best for extracapsular extension.
